Golden Biotechnology Corporation
- Country
- π¨π³China
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 51
- Market Cap
- -
Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)β’ Click on a phase to view related trials
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Golden Biotechnology Corporation
- Target Recruit Count
- 124
- Registration Number
- NCT04523181
- Locations
- πΊπΈ
Franciscan Health Michigan City, Michigan City, Indiana, United States
πΊπΈAscension.Via Christi Research, Wichita, Kansas, United States
πΊπΈAdventist Healthcare Shady Grove Medical Center, Rockville, Maryland, United States
Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Golden Biotechnology Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT03823352
- Locations
- π·πΊ
City Clinical Hospital n.a. S.P.Botkin, Moscow, Russian Federation
π·πΊTula Regional Clinical Hospital, Tula, Russian Federation
A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Golden Biotechnology Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT03625102
- Locations
- π¨π³
Chung Shan Medical University Hospital, Taichung, Taiwan
A Trial of Antroquinonol in Patients With Atopic Dermatitis
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Golden Biotechnology Corporation
- Target Recruit Count
- 14
- Registration Number
- NCT03622463
- Locations
- π¨π³
Chung Shan Medical University Hospital, Taichung, Taiwan
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Golden Biotechnology Corporation
- Target Recruit Count
- 52
- Registration Number
- NCT03310632
- Locations
- πΊπΈ
Florida Hospital Tampa, Tampa, Florida, United States
πΊπΈCTCA Southeastern Regional Medical Center, Newnan, Georgia, United States
πΊπΈHenry Ford Health System, Detroit, Michigan, United States
- Prev
- 1
- 2
- Next